136 related articles for article (PubMed ID: 28570008)
1. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N
Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008
[TBL] [Abstract][Full Text] [Related]
2. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
[TBL] [Abstract][Full Text] [Related]
4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
5. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma.
Miller K; Price JH; Dobbs SP; McClelland RH; Kennedy K; McCluggage WG
J Clin Pathol; 2008 May; 61(5):652-7. PubMed ID: 18006668
[TBL] [Abstract][Full Text] [Related]
7. Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites.
Köbel M; Turbin D; Kalloger SE; Gao D; Huntsman DG; Gilks CB
Int J Gynecol Pathol; 2011 Jul; 30(4):366-71. PubMed ID: 21623201
[TBL] [Abstract][Full Text] [Related]
8. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
Ruba S; Doherty D; Stewart CJR
Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502
[TBL] [Abstract][Full Text] [Related]
9. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
Kim HN; Woo HY; DO SI; Kim HS
In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
[TBL] [Abstract][Full Text] [Related]
10.
Na K; Sung JY; Kim HS
Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
[TBL] [Abstract][Full Text] [Related]
11. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
12. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
13. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
[TBL] [Abstract][Full Text] [Related]
14. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
[TBL] [Abstract][Full Text] [Related]
15. Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
Kwon HJ; Song SY; Kim HS
Anticancer Res; 2021 Mar; 41(3):1579-1586. PubMed ID: 33788752
[TBL] [Abstract][Full Text] [Related]
16. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
17. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
[TBL] [Abstract][Full Text] [Related]
18. Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
Casey L; Singh N
Surg Pathol Clin; 2019 Jun; 12(2):515-528. PubMed ID: 31097113
[TBL] [Abstract][Full Text] [Related]
19. Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology.
Bansal A; Srinivasan R; Rohilla M; Sundaram A; Rai B; Rajwanshi A; Suri V; Saha SC; Gupta N; Gupta P; Dey P
Am J Clin Pathol; 2020 Jun; 154(1):103-114. PubMed ID: 32271370
[TBL] [Abstract][Full Text] [Related]
20. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
